Please enable JS

Investors

Press Releases

 
Press Releases
  Date Title View
Sep 14, 2004
CAMBRIDGE, Mass., Sept. 14 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on sugar sequencing technology, announced today that its Chairman and Chief Executive Officer, Alan Crane, will present at the ThinkEquity Partners Growth Conference on Tuesday, September 21, 2...
Sep 2, 2004
CAMBRIDGE, Mass., Sept. 2 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on sugar sequencing technology, announced today that its Chairman and Chief Executive Officer Alan Crane will present at the Bear Stearns 17th Annual Healthcare Conference on Monday September 13...
Aug 16, 2004
CAMBRIDGE, Mass., Aug. 16 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on sugar sequencing technology, today announced its financial results for the quarter ended June 30, 2004. The Company reported a net loss of $2.9 million for the quarter ended June 30, 2004 com...
Jul 23, 2004
CAMBRIDGE, Mass., July 23 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) announced today that its Chairman and Chief Executive Officer Alan Crane will present at the Banc of America Securities "New Products, New Paradigms in Health Care" Conference on Friday, July 30, 2004 at 11:45 am Eastern Standard Time at the ...
Jun 28, 2004
CAMBRIDGE, MA - June 28, 2004 – Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) announced today that the underwriters of the Company's recent initial public offering of 5,350,000 shares of common stock exercised in full their over-allotment option to purchase an additional 802,500 shares of common stock at the ini...
Jun 21, 2004
CAMBRIDGE, Mass., June 21 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. announced today the pricing of its initial public offering of 5,350,000 shares of common stock at a price of $6.50 per share. All of the shares are being offered by Momenta. Momenta also granted to the underwriters a thirty-day option to purchase up to an a...
FirstPrevious
...
40
= add release to Briefcase